Ratings Sino Biological,Inc.

Equities

301047

CNE100004Q23

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
70.51 ^CNY	-0.14%		+2.62%	-14.43%

Apr. 28	Sino Biological,Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 26	Sino Biological,Inc. completed the acquisition of SignalChem Biotech Inc. from Signalchem Lifesciences Corporation.	CI

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

With a 2024 P/E ratio at 27.58 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
SINO BIOLOGICAL,INC.	-14.43%	1.24B	-
MODERNA, INC.	+26.28%	48.09B	B-
IQVIA HOLDINGS INC.	-3.99%	40.43B	B
LONZA GROUP AG	+46.73%	40.62B	A
CELLTRION, INC.	-6.20%	28.36B	C
ICON PUBLIC LIMITED COMPANY	+6.36%	24.89B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	19.01B	B
MEDPACE HOLDINGS, INC.	+27.58%	12.09B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.8B	C+
BIO-TECHNE CORPORATION	-2.02%	11.88B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes